Effect of bare-metal nitinol stent implantation and paclitaxel-eluting nitinol stent implantation on vascular response in the superficial femoral artery lesion assessed on intravascular ultrasound

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1451-1458

  Miki, Kojiro ^a   Fujii, Kenichi ^a   Kawasaki, Daizo ^b   Fukunaga, Masashi ^a   Nishimura, Machiko ^a   Horimatsu, Tetsuo ^a   Saita, Ten ^a   Tamaru, Hiroto ^a   Imanaka, Takahiro ^a   Shibuya, Masahiko ^a   Masutani, Motomaru ^a   Ohyanagi, Mitsumasa ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Endovascular therapy; Intravascular ultrasound; Paclitaxel eluting nitinol stent; Restenosis; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; ALLOY; ANTINEOPLASTIC AGENT; NITINOL; PACLITAXEL;

AGED; ANGIOGRAPHY; ARTERY LESION; ARTICLE; BARE METAL NITINOL STENT; BLOOD VESSEL PARAMETERS; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; ENDOVASCULAR SURGERY; FEMALE; FEMORAL ARTERY; HUMAN; INTRAVASCULAR ULTRASOUND; LUMEN LOSS; MALE; NEOINTIMA; NITINOL STENT; OBSERVER VARIATION; PACLITAXEL ELUTING NITINOL STENT; RETROSPECTIVE STUDY; STENT; STENT VOLUME; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ELUTING STENT; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLOYS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG-ELUTING STENTS; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; PACLITAXEL; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84901359958     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1508     Document Type: Article

References (31)

1. Rowe VL, Lee W, Weaver FA, Etzioni D. Pattern of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg 2009; 49: 910-917.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC Working Group: TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1-S296.
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Haris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-S67.
4. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-1888.
5. Vogel TR, Shindelman LE, Nackman GB, Graham AM. Efficacious use of nitinol stents in the femoral and popliteal arteries. J Vasc Surg 2003; 38: 1178-1184.
6. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115: 2745-2749.
7. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011; 4: 495-504.
8. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013; 61: 2417-2427.
9. Kawarada O, Higashimori A, Noguchi M, Waratani N, Yoshida M, Fujihara M, et al. Duplex criteria for in-stent restenosis in the superficial femoral artery. Catheter Cardiovasc Interv 2013; 81: E199-E205.
10. Cheneau E, Leborgne L, Mintz GS, Kotani J, Pichard AD, Satler LF, et al. Predictors of subacute stent thrombosis: Results of a systematic intravascular ultrasound study. Circulation 2003; 108: 43-47.
11. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS): A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-1492.
12. Fukuda D, Kawarabayashi T, Tanaka A, Nishibori Y, Taguchi H, Nishida Y, et al. Lesion characteristics of acute myocardial infarction: An investigation with intravascular ultrasound. Heart 2001; 85: 402-406.
13. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995; 26: 720-724.
14. Kobayashi Y, Honda Y, Christie GL, Teirstein PS, Bailey SR, Brown CL 3rd, et al. Long-term vessel response to a self-expanding coro nary stent: A serial volumetric intravascular ultrasound analysis from the ASSURE Trial: A stent vs. stent ultrasound remodeling evaluation. J Am Coll Cardiol 2001; 37: 1329-1334.
15. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (FAST). Circulation 2007; 116: 285-292.
16. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009; 74: 1090-1095.
17. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
18. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
19. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
20. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation 2002; 106: 1505-1509.
21. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358: 689-699.
22. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111: 2257-2273.
23. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-769.
24. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995; 95: 1869-1876.
25. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
26. Ishihara T, Iida O, Awata M, Nanto K, Nanto S, Uematsu M. Angioscopic assessment of early phase arterial repair after paclitaxel-coated nitinol drug-eluting stent implantation in the superficial femoral artery. Circ J 2013; 77: 1838-1843.
27. Schroeder S, Baumbach A, Mahrholdt H, Haase KK, Oberhoff M, Herdeg C, et al. The impact of untreated coronary dissections on acute and long-term outcome after intravascular ultrasound guided PTCA. Eur Heart J 2000; 21: 137-145.
28. Sheris SJ, Canos MR, Weissman NJ. Natural history of intravascular ultrasound-detected edge dissections from coronary stent deployment. Am Heart J 2000; 139: 59-63.
29. Yang TH, Kim DI, Jin HY, Cho YW, Chung SR, Kim DK, et al. "Angiographic late catch-up" phenomenon after sirolimus-eluting stent implantation. Int J Cardiol 2012; 160: 48-52.
30. Collet CA, Costa JR, Abizaid A, Chamié D, Staico R, Costa R, et al. Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents. JACC Cardiovasc Interv 2011; 4: 1067-1074.
31. Ejiri K, Ishihara M, Dai K, Miki T, Inoue I, Kawagoe T, et al. Threeyear follow-up of sirolimus-eluting stents vs. bare metal stents for acute myocardial infarction. Circ J 2012; 76: 65-70.